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ABSTRACT
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly lethal malignancy that 
responds poorly to current therapeutic modalities. In an effort to develop novel 
therapeutic strategies, we found downregulation of miR-29 in pancreatic cancer cells, 
and overexpression of miR-29a sensitized chemotherapeutic resistant pancreatic 
cancer cells to gemcitabine, reduced cancer cell viability, and increased cytotoxicity. 
Furthermore, miR-29a blocked autophagy flux, as evidenced by an accumulation 
of autophagosomes and autophagy markers, LC3B and p62, and a decrease in 
autophagosome-lysosome fusion. In addition, miR-29a decreased the expression 
of autophagy proteins, TFEB and ATG9A, which are critical for lysosomal function 
and autophagosome trafficking respectively. Knockdown of TFEB or ATG9A inhibited 
autophagy similar to miR-29a overexpression. Finally, miR-29a reduced cancer cell 
migration, invasion, and anchorage independent growth. Collectively, our findings 
indicate that miR-29a functions as a potent autophagy inhibitor, sensitizes cancer cells 
to gemcitabine, and decreases their invasive potential. Our data provides evidence 
for the use of miR-29a as a novel therapeutic agent to target PDAC.
INTRODUCTION
Pancreatic Ductal Adenocarcinoma (PDAC) is one 
of the most lethal forms of human malignancies worldwide 
with poor prognoses [1]. In the United States, PDAC is the 
fourth leading cause of cancer related deaths [2] and is 
projected to become the second leading cause of cancer 
deaths by 2030 [3]. PDAC is often undiagnosed until it has 
metastasized and these advanced tumors display resistance 
to existing therapeutic modalities. Although there have 
been recent improvements in combination chemotherapies 
such as Nab-Paclitaxel/Gemcitabine and FOLFIRINOX 
[4, 5], the overall 5-year survival rate has not exceeded 
8% [2]. Furthermore, PDAC has a well-characterized 
mutational profile that plays a key role in disease onset and 
progression (>90% cases with KRAS mutations and >50% 
with inactivating mutations in p53, CDKN2A, or SMAD4) 
[6], but the knowledge of these genetic perturbations 
has yet to yield targeted therapies. The lack of effective 
treatments and early detection necessitates the critical 
need to further dissect molecular mechanisms associated 
with PDAC progression to develop novel and effective 
therapeutic strategies for improving patient survival.
Macroautophagy, herein referred to as autophagy, is 
the process in which cells degrade internal constituents 
for the maintenance of cellular homeostasis and survival 
under stress conditions [7]. When autophagy is induced, 
cytoplasmic components are sequestered into double-
membrane vesicles called autophagosomes, which then 
fuse with lysosomes. Subsequently, the hydrolases of 
the lysosomal compartments degrade cytoplasmic cargo 
and release the basic cellular building blocks into the 
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cytosol for recycling [7]. Recent studies document that 
the upregulation of autophagy can serve as a survival 
mechanism in various malignancies [8–19], including 
PDAC tumor growth and progression [15–17]. These 
reports have paved the way for clinical trials utilizing 
hydroxychloroquine (HCQ), a lysosomotropic agent, 
in PDAC patients to inhibit autophagy as a means of 
therapy (clinicaltrials.gov NCT01273805). However, 
HCQ is associated with toxicity and off-target effects 
such as neuromyotoxicity [20], retinopathy [21, 22], and 
cardiomyopathy [23, 24].
Increasing evidence suggests that microRNA 
(miRNA)-based therapeutics have limited off-target effects 
and could emerge as novel therapeutic agents for various 
human diseases including cancer [25–31]. miRNAs are 
conserved small non-coding RNAs that regulate post-
transcriptional gene expression [32, 33]. These small 
molecules are abundantly expressed in normal tissue, and are 
often misregulated in disease states. Restored expression of 
downregulated miRNAs has been suggested to be beneficial 
in therapeutically targeting cancer [34–36]. We and others 
have recently found miR-29 to be downregulated in PDAC 
[37–39]. Of importance, overexpression of miR-29 in 
stromal cells reduced the accumulation of stromal proteins 
and cancer colony formation in direct co-cultures [39].
In this study, we address the role of miR-29 in 
pancreatic cancer cells. We found downregulation of 
miR-29 in a range of pancreatic cancer cell lines, and 
restored expression of miR-29a blocked autophagy flux by 
inhibiting expression of key autophagy proteins, TFEB and 
ATG9A. Furthermore, miR-29a overexpression sensitized 
chemoresistant pancreatic cancer cells to gemcitabine and 
reduced their invasive potential. Our findings provide 
evidence for the use of miR-29a as a novel therapeutic 
agent to target PDAC.
RESULTS
miR-29a sensitizes chemotherapeutic resistant 
pancreatic cancer cell lines to gemcitabine 
treatment
Previously, we observed a global and epithelial-
specific decrease in miR-29 expression in the pancreata 
of a well-characterized pancreatic cancer mouse model, 
LSL-KRasG12D; Pdx1Cre, and human PDAC patients 
[39]. To understand the function of miR-29 in pancreatic 
cancer cells, we initially measured the expression levels of 
miR-29 in five pancreatic cancer cell lines (Panc-1, MIA 
PaCa-2, COLO 357, BxPC-3, and AsPC-1) compared to 
two normal human pancreatic ductal epithelial cell lines 
(HPNE and HPDE). There was a significant decrease 
in miR-29a and miR-29b expression in four out of five 
pancreatic cancer cell lines compared to normal human 
pancreatic ductal epithelial cells and levels of miR-29c 
were lower in three out of five pancreatic cancer cell lines 
(Figure 1A). We have previously reported that miR-29a 
is the most abundantly expressed miR-29 family member 
in the human pancreas and in pancreatic stellate cells [39] 
and also found that miR-29a is the most highly expressed 
miR-29 family member in the normal human pancreatic 
epithelial cell line, HPNE (Supplementary Figure S1). 
Therefore, we focused on miR-29a for functional studies.
One of the major limitations in treating PDAC is 
that cancer cells acquire resistance to existing chemo and 
radiation therapeutic modalities, including gemcitabine 
[40]. Furthermore, pancreatic cancer cells are surrounded 
by dense fibrotic stroma, which is known to impair drug 
delivery to the tumor core [41]. Previously, we showed 
that overexpression of miR-29a in pancreatic stellate cells, 
the major stromal cells responsible for fibrotic stroma, 
reduced extracellular matrix protein accumulation and 
cancer growth in co-cultures, suggesting its potential 
use as a novel therapeutic agent in normalizing stromal 
abundance to target PDAC [39]. To test the feasibility of 
combining miR-29a with gemcitabine, a standard therapy, 
we investigated the effect of miR-29a overexpression on 
viability of known gemcitabine resistant pancreatic cancer 
cell lines, Panc-1 and MIA PaCa-2 [42]. Overexpression 
of miR-29a alone did not significantly reduce the viability 
of cancer cells, but the addition of gemcitabine resulted 
in a significant decrease at various concentrations starting 
at 0.1μM (Figure 1B). Furthermore, miR-29a did not 
have any additive effect on cell viability in gemcitabine 
sensitive PDAC cell line, COLO 357 [43], to drug 
treatment (Supplementary Figure S2).
Evasion of cell death is a crucial event during 
malignant transformation of pancreatic cancer cells. 
Initially, we determined the cytotoxic effects of miR-29a in 
combination with gemcitabine on PDAC cell lines resistant 
to gemcitabine (Panc-1 and MIA PaCa-2) by measuring 
the release of lactate dehydrogenase (LDH) [44, 45]. 
There was a significant increase in LDH from the Panc-
1 and MIA PaCa-2 cells overexpressing miR-29a upon 
gemcitabine treatment, indicating that miR-29a increases 
cytotoxicity in combination with gemcitabine (Figure 1C 
and Supplementary Figure S3). We also observed increased 
caspase-3/7 activity (Figure 1D and Supplementary 
Figure S4A) and cleaved caspase-3 levels (Figure 1E and 
Supplementary Figure S4B) in miR-29a overexpressing 
cancer cells upon gemcitabine treatment compared to cancer 
cells treated with gemcitabine alone. Taken together, these 
findings indicate that miR-29a sensitizes pancreatic cancer 
cells to gemcitabine treatment and provides compelling 
evidence for its use in combination with gemcitabine as a 
novel therapeutic strategy to target PDAC.
miR-29a inhibits autophagy flux in pancreatic 
cancer cells
Pancreatic cancer cells induce autophagy as a 
survival mechanism to escape gemcitabine induced cell 
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death [17–19]. Therefore, we sought to determine the 
effect of miR-29 on autophagy, to determine whether the 
increased sensitivity and cytotoxic effects of gemcitabine 
in chemotherapeutic resistant pancreatic cancer cells is 
due to alterations in autophagy. LC3B is a widely used 
marker to monitor autophagy levels [46]. Normally, 
LC3B resides in the cytoplasm (LC3BI), and upon 
initiation of autophagy, it is conjugated with phosphatidyl-
ethanolamine (LC3BII) to facilitate formation and 
expansion of the autophagosome membrane [47–51].
To elucidate the effects of miR-29a on PDAC 
autophagy, Panc-1 cells, which have high basal levels of 
autophagy [17], were transfected with miR-29a or mimic 
control and LC3B levels were assessed by western blot 
analysis. There was a marked increase in LC3B upon 
miR-29a overexpression in Panc-1 cells (Figure 2A). 
Similar observations were found in MIA PaCa-2 and 
COLO 357 cells (Supplementary Figure S5A and S5B). 
An increase in LC3B levels can indicate an upregulation 
of autophagy or a blockage of autophagy flux [52]. We 
therefore examined the expression of an autophagic 
substrate, p62, in conjunction with LC3B. p62/SQSTM1 
is efficiently degraded upon autophagy induction and 
serves as an indicator of autophagic turnover [52]. An 
increase in p62 levels correlates with an inhibition in 
autophagy, whereas a decrease indicates induction of 
autophagy [53]. There was a robust accumulation of 
p62 in miR-29a overexpressing cancer cells (Figure 2A, 
Supplementary Figure S5A, and S5B), suggesting that 
miR-29a causes a late stage blockage in autophagy flux. 
Figure 1: miR-29a increased sensitivity of chemoresistant PDAC cells to gemcitabine treatment. A. qPCR analysis of miR-
29 family members in normal human ductal epithelial cell lines (HPNE and HPDE) and pancreatic cancer cell lines (Panc-1, MIA PaCa-2, 
COLO 357, BxPC-3, AsPC-1) (n=4). Data represented as average fold change (ΔΔCT) ± standard error of the mean (S.E.M.) B. Pancreatic 
cancer cell lines (Panc-1 and MIA PaCa-2) were seeded into 96-well plates, transfected with control (CTRL) or miR-29a mimics, treated 
with indicated concentrations of gemcitabine (GEM) for 24 hours post-transfection, and viability was measured at 72 hours post-treatment 
using the Cell Counting Kit-8 (CCK-8). Average absorbance (A450) is represented (n=8) ± S.E.M. C. Panc-1 cells were transfected with 
CTRL or miR-29a mimics, treated with 10μM GEM for 48 hours and lactate dehydrogenase (LDH) release was determined by substrate 
based activity assay (fluorescence 560/590nm). Average relative percent cytotoxicity are represented (n=3-4) ± S.E.M. D. Panc-1 cells were 
transfected with CTRL or miR-29a mimics. 24 hours post-transfection cells were treated with 10μM GEM for 24 hours, lysed, and caspase 
activity was determined by absorbance using Apo-ONE Homogeneous Caspase-3/7 Assay according to manufacturer’s protocol. Average 
relative fluorescence (RFU, 490/530nm) are represented (n=4) ± S.E.M. E. Panc-1 transfected with CTRL or miR-29a mimics, treated with 
10μM GEM for 12 hours and 15ug of total cell protein lysate was subjected to western blot analysis for procaspase-3, cleaved caspase-3, 
and GAPDH was used as loading control. Relative quantification of band intensities normalized to GAPDH are shown below respective 
blots. All experiments were repeated 3-4 times and representative data is presented. *p<0.05, **p<0.01, non-significant (n.s.).
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It is possible that the increase in p62 could be due to an 
indirect transcriptional upregulation rather than inhibition 
of autophagy. Therefore, we measured p62 transcript 
levels and found no significant change (Supplementary 
Figure S6), indicating that the p62 accumulation is due to 
a perturbation in autophagy.
Chloroquine (CQ) is a lysosomotropic agent that 
inhibits autophagy by raising lysosomal pH [54]. The 
increase in lysosomal pH permits autophagosome-
lysosome fusion but prevents degradation and 
autolysosomal turnover [55]. To further assess the effect 
of miR-29a on autophagy flux, miR-29a or mimic control 
was transiently expressed in Panc-1 cells and then treated 
with CQ. Our results showed a net increase in LC3BI 
and II and p62 accumulation in control cells upon CQ 
addition. However, when miR-29a is overexpressed, 
prior to CQ treatment, the net difference of LC3B and 
p62 between miR-29a alone compared to miR-29a and 
CQ combination treatment was low, as miR-29a had 
already blocked autophagy (Figure 2A). These results 
were further recapitulated in MIA PaCa-2 and COLO 
357 cells (Supplementary Figure S5A and S5B). Similar 
to CQ, BafilomycinA1 (BafA1) functions as a late stage 
inhibitor of autophagy by raising lysosomal pH [56] 
and also blocks autophagosome-lysosome fusion [57]. 
Treatment of Panc-1 and MIA PaCa-2 with other late stage 
autophagy inhibitors, CQ and BafA1, resulted in p62 and 
LC3B accumulation similar to miR-29a overexpression 
(Supplementary Figure S7).
Pancreatic cancer cells have been previously 
shown to induce autophagy and acquire resistance to 
chemotherapy [16, 58, 59]. To verify the functional 
effect of miR-29a mediated blockage of autophagy flux 
on gemcitabine sensitization, we evaluated the effects 
of miR-29a on cancer cell viability in comparison with 
BafA1. Similar to miR-29, treatment of cancer cells 
with gemcitabine in combination with BafA1 decreased 
cancer cell viability (Panc-1 and MIA PaCa-2) compared 
to gemcitabine alone (Figure 2B and Supplementary 
Figure S8). To further elucidate the effect of miR-29a 
and gemcitabine combination on pancreatic cancer cell 
autophagy, miR-29a expressing Panc-1 and MIA PaCa-
2 cells were treated with gemcitabine and subjected to 
LC3B and p62 western blot analysis (Supplementary 
Figure S9). Similar to previous reports, Panc-1 and MIA 
PaCa-2 cells treated with gemcitabine alone exhibited a 
marked increase in LC3BII and decrease in p62, indicating 
autophagy induction. However, miR-29a overexpressing 
cancer cells did not exhibit any net decrease in p62 with 
an increase in LC3B levels upon gemcitabine treatment 
due to a miR-29a mediated inhibition of autophagy 
(Supplementary Figure S9). Taken together, these findings 
suggest that miR-29a functions as a late stage autophagy 
inhibitor and sensitizes chemoresistant pancreatic cancer 
cell lines (Panc-1 and MIA PaCa-2) to gemcitabine 
treatment.
miR-29a inhibits autophagosome-lysosome 
fusion
During autophagy, autophagosomes fuse with 
lysosomes where lysosomal hydrolases degrade 
Figure 2: miR-29a overexpression causes blockage in autophagy flux. A. Panc-1 cells were transfected with CTRL or miR-29a 
mimics. Following transfection, cells were treated with 25μM Chloroquine (CQ) and 5ug of total cell lysates were subjected to western blot 
analysis for p62 and LC3B, and GAPDH was used as loading control. Relative quantification of band intensities normalized to GAPDH are 
shown below respective blots. B. Panc-1 cells were transfected with CTRL or miR-29a mimics and treated with and without 10μM GEM. 
In parallel, Panc-1 cells were treated with 10μM GEM alone or in combination with 10μM BafA1. 48 hours post GEM treatment, viability 
was determined using CCK-8 assay kit. Average relative absorbance (A450) normalized to respective controls is presented (n=6) ± S.E.M. 
All experiments were repeated 3-4 times and representative data is presented. *p<0.05, **p<0.01, and ***p<0.001.
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autophagosomal contents to be recycled back into 
the cytoplasm [7]. To understand the mechanisms 
by which miR-29a mediates blockage of autophagy 
flux, we evaluated its impact on autophagosomes and 
their interactions with lysosomes. Panc-1 cells stably 
expressing GFP-LC3B were transfected with miR-29a 
or control mimics, treated with 25μM CQ, and stained 
with lysosomal-associated membrane protein 2 (LAMP-
2), a lysosomal marker. In subsequent image analysis, 
we observed a two-fold increase in accumulation of 
autophagosomes/autophagolysosomes in miR-29a 
overexpressing cells (Figure 3A, 3B, and Supplementary 
Figure S10). Furthermore, overexpression of miR-
29a resulted in a >35% decrease in LC3B/LAMP-2 
colocalization at basal levels and >60% decrease in miR-
29a overexpressing cells treated with CQ, compared to CQ 
alone (Figure 3A, 3C, and Supplementary Figure S11), 
indicating miR-29a mediated blockage of autophagosome-
lysosome fusion.
miR-29a downregulates critical autophagy 
proteins TFEB and ATG9A
To address the mechanisms by which miR-29a 
mediates blockage of autophagy at late stages, we 
searched for potential autophagy related genes that are 
targeted by miR-29a using four prediction algorithms 
(TargetScan, PicTar, PITA, and miRanda). We found 
that both transcription factor EB (TFEB) and autophagy-
related protein 9A (ATG9A) contain phylogenetically 
conserved miR-29 binding sites in their 3’-UTRs (Figure 
4A). TFEB is a transcription factor and member of the 
MiT/TFE family, which has been shown to be an integral 
part of the lysosome and autophagy machinery [60]. 
Upregulation of MiT/TFE factors has been implicated in 
various cancers [61–63], and a recent study documented 
that upregulation of TFEB contributes to increased 
autophagy in PDAC [63]. Furthermore, knockdown 
of TFEB impaired growth and metabolism of PDAC 
cells by disrupting lysosomal catabolism in autophagy 
[63]. Among >30 essential autophagy-related (ATG) 
genes [64], ATG9A is the only transmembrane protein 
[65] and has been shown to facilitate trafficking lipid 
membrane from the Golgi network and endosomes to 
the formation of autophagosomes [66, 67]. ATG9A has 
been shown to be upregulated in some carcinomas [68, 
69] but has yet to be studied in PDAC. In our western 
blot analysis, overexpression of miR-29a in pancreatic 
cancer cells resulted in a marked downregulation of 
both TFEB and ATG9A expression (Figure 4B and 
Figure 3: miR-29a inhibits autophagosome-lysosome fusion. A. Panc-1 stably expressing GFP-LC3B were transfected with 
CTRL or miR-29a mimics. Following transfection, cells were treated with 25μM CQ. Cells were fixed and stained for lysosomal-associated 
membrane protein 2 (LAMP-2). B. Image analysis was conducted to quantify number of GFP-LC3B positive compartments per cell, and 
averages are presented ± S.E.M. C. Colocalization was calculated based on GFP-LC3B and LAMP-2 staining, and average percentage 
of colocalization is presented ± S.E.M. Experiment was repeated 3 times and representative data is presented. *p<0.05, **p<0.01, non-
significant (n.s.).
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Supplementary Figure S12). As miRNAs regulate the 
expression of multiple target mRNAs, to test whether 
miR-29a regulates expression of GAPDH, an endogenous 
control, we conducted target prediction analysis 
(Targetscan) and confirmed that GAPDH is not a target 
of miR-29a (data not shown), ensuring its use as a proper 
loading control in our western blot analysis.
As we observed downregulation of TFEB and 
ATG9A with miR-29a overexpression, to verify whether 
miR-29a directly regulates their expression, TFEB 
Figure 4: miR-29a downregulates TFEB and ATG9A to inhibit autophagy. A. Schematic representation of the miR-29 family 
members and 3’-UTR binding sites of miR-29 targets as well as mutated binding sites used in Luciferase Assays: Transcription Factor 
EB (TFEB) and Autophagy-related protein 9A (ATG9A). All three miR-29 family members (miR-29a, miR-29b, and miR-29c) have 
identical seed sequences. Conserved miR-29 binding sites in the 3’-UTR of mRNA transcripts encoding ATG9A and TFEB are depicted in 
bold. B. 10ug of total protein cell lysates from Panc-1 transfected with CTRL or miR-29a mimics were subjected to western blot analysis 
for TFEB, ATG9A, and GAPDH. Relative quantification of band intensities normalized to GAPDH are shown below respective blots. 
C. Relative firefly luciferase activity from TFEB and ATG9A 3’ UTR wild type (WT) and mutant (mut) reporter constructs following co-
transfection into Panc-1 cells with control or miR-29a mimics. All readouts were normalized to renilla luciferase activity for each well. 
Average relative luminesce normalized to respective controls is presented (n=6) ± S.E.M. D. 5ug of total protein cell lysates from Panc-1 
cells were transfected with CTRL, miR-29a mimics, siCTRL, siTFEB, or siATG9A. 24 hours post-transfection, total protein was harvested 
and subjected to western blot analysis for p62 and LC3B, and GAPDH was used as loading control. Quantification of band intensities 
normalized to GAPDH and relative to control are shown below respective blots. All experiments were repeated 3 times and representative 
data is presented.
Oncotarget71641www.impactjournals.com/oncotarget
and ATG9A 3’UTR luciferase reporter plasmids were 
developed for regions containing miR-29 predicted 
binding sites. Both wild type and mutated binding sites 
(Figure 4A) were cloned into the 3’UTR downstream 
of the luciferase open reading frame. When reporter 
plasmids with wild type miR-29a binding sites were 
co-transfected with miR-29a mimics into cancer cells, 
we found a significant repression of luciferase activity. 
However, when the 3’UTRs were mutated, miR-29a no 
longer has the ability to repress luciferase activity of both 
TFEB and ATG9A, demonstrating that miR-29a represses 
TFEB and ATG9A expression by directly interacting at 
the predicted sites. Consistently, we observed higher 
ATG9A and TFEB expression in pancreatic cancer cells 
that have low miR-29a expression (Panc-1 and MIA 
PaCa-2), compared to normal pancreatic epithelial cell 
line (HPNE) and cancer cell line with high miR-29 
expression (AsPC-1) (Supplementary Figure S13). Taken 
together, our data implicates that miR-29a downregulates 
TFEB and ATG9A through direct interactions with the 
3’UTR binding sites.
Next, we sought to determine the effects of TFEB 
and ATG9A depletion on PDAC autophagy using siRNA 
mediated knockdown of TFEB or ATG9A. Knockdown of 
these two genes resulted in an accumulation of LC3B and 
p62 similar to miR-29a overexpression (Figure 4D and 
Supplementary Figure S14). Furthermore, knockdown 
of TFEB and ATG9A led to a significant increase in 
accumulation of GFP-LC3B positive vesicles (Figure 
5). TFEB knockdown resulted in a ~50% increase of 
autophagosome accumulation (Figure 5A and 5B), 
whereas ATG9A knockdown caused a >100% increase 
in autophagosome accumulation (Figure 5A and 5B). 
Although knockdown of TFEB blocked autophagy, as 
indicated by an increased accumulation in p62 and LC3B 
(Figure 4C), we did not find a significant difference in 
GFP-LC3B and LAMP-2 colocalization, suggesting 
that the increase in GFP-LC3B positive vesicles were 
mostly due to accumulation of autophagolysosomes 
(Figure 5A and 5B). Whereas, knockdown of ATG9A 
resulted in a robust 2-fold decrease in colocalization 
of LC3B and LAMP-2, demonstrating that miR-29a 
inhibits autophagosome-lysosome fusion predominately 
by deregulation of ATG9A. Taken together, our results 
suggests that miR-29a inhibits autophagy flux through the 
downregulation of TFEB and ATG9A expression, which 
Figure 5: Knockdown of TFEB and ATG9A results in decreased autophagosomal-lysosomal fusion. A. Panc-1 cells stably 
expressing GFP-LC3B were transfected with either CTRL or miR-29a mimics in parallel to cells transfected with siCTRL, siTFEB, or 
siATG9A. Following transfection, cells were fixed and stained for lysosomal-associated membrane protein 2 (LAMP-2). B. Image analysis 
was conducted to quantify number of GFP-LC3B positive compartments per cell, and averages are presented ± S.E.M. C. Colocalization 
was calculated based on GFP-LC3B and LAMP-2 staining, and average percentage of colocalization is presented ± S.E.M. All experiments 
were repeated 3 times and representative data is presented. **p<0.05, **p<0.01, ***p<0.001 non-significant (n.s.).
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are critical for lysosomal function and autophagosome 
trafficking respectively.
miR-29a reduces pancreatic cancer cell invasion 
in vitro
Prior studies have also found that miR-29 is 
downregulated in a wide variety of carcinomas, including 
breast, colorectal, and prostate, and its reintroduction 
had anti-metastatic effects [70–72]. Furthermore, 
increase in autophagy has been shown to enhance the 
invasive potential of cancer cells and promote epithelial-
mesenchymal transition (EMT) [11, 12]. As we observed 
downregulation of miR-29 in pancreatic cancer cells 
and its subsequent overexpression inhibited autophagy, 
we performed a series of in vitro functional studies to 
evaluate the effect of miR-29a on the invasive potential 
of pancreatic cancer cells. To determine the effect of miR-
29a on cancer cell migration and invasion, Panc-1 and 
MIA PaCa-2 cells were transfected with control or miR-
29a mimics and seeded in transwell assays. Compared to 
control cells, significantly fewer miR-29a overexpressing 
cancer cells migrated through transwell membranes and 
invaded through matrigel-precoated membranes (Figure 
6A, 6B, Supplementary Figure S15A, and S15B).
EMT is known to enhance the migration/invasion of 
pancreatic cancer cells and resistance to apoptosis [73–75]. 
As miR-29a reduced the migration and invasion potential 
of pancreatic cancer cells, we sought to determine its 
effect on EMT. As expected, overexpression of miR-29a in 
pancreatic cancer cells increased expression of epithelial 
marker, E-cadherin [74] and decreased mesenchymal 
marker, Vimentin [74] (Figure 6C).
We next tested the effect of miR-29a overexpression 
on anchorage independent growth of pancreatic cancer 
cells using soft agar assays. There was a significant 
decrease in the number of anchorage independently 
growing cancer colonies in miR-29a overexpressing 
PDAC cells compared to cells expressing control mimic 
(Figure 6D and Supplementary Figure S16). Our data 
demonstrates the anti-invasive potential of miR-29a 
evidenced by a reduction in migration, invasion, and 
anchorage independent growth of pancreatic cancer cells.
DISCUSSION
For the first time, we demonstrate that miR-29a 
functions as a potent autophagy inhibitor, sensitizes 
chemoresistant cancer cells to gemcitabine, and 
reduces the invasive potential of pancreatic cancer cells 
(Figure 7). Increasing evidence documents the role of 
autophagy in cancer pathogenesis, and has proven to be 
a novel therapeutic target [8–17]. We found consistent 
downregulation of miR-29 in pancreatic cancer cells, 
and its overexpression inhibited autophagy, evidenced 
by increased accumulation of autophagosomes/
autophagolysosomes and autophagy markers, LC3B and 
p62. Furthermore, miR-29a decreased autophagosome-
lysosome fusion, as evidenced by a significant decrease 
in colocalization of LC3B and LAMP-2, autophagosomal 
and lysosomal markers respectively. Taken together, our 
results suggest that miR-29a functions as a late stage 
autophagy inhibitor and blocks autophagosome-lysosome 
fusion.
To determine the mechanisms of miR-29a 
mediated inhibition of autophagy, we identified two 
critical autophagy proteins, TFEB and ATG9A, which 
have phylogenetically conserved miR-29 binding sites 
in their 3’-UTRs. As expected, overexpression of miR-
29a caused a marked reduction of TFEB and ATG9A 
expression. TFEB, a transcription factor essential for 
lysosomal function, is highly activated in PDAC [60] 
and its knockdown reduces tumor progression and 
impairs autophagy due to lysosomal dysfunction [63]. 
ATG9A is the only transmembrane ATG protein, and 
facilitates membrane trafficking of autophagosomes [76, 
77]. Upregulation of ATG9A has been well documented 
in other carcinomas [68, 69]. Knockdown of TFEB 
or ATG9A caused a late stage blockage in autophagy 
similar to miR-29a overexpression. Interestingly, 
knockdown of ATG9A or TFEB increased the 
accumulation of LC3B positive compartments, but only 
the knockdown of ATG9A blocked autophagosome-
lysosome fusion. As ATG9A functions in vesicular 
trafficking, reduced expression of ATG9A is likely 
to cause perturbations in autophagosome trafficking 
and prevent them from fusing with lysosomes. 
Whereas, TFEB knockdown mediated accumulation 
of autophagolysosomes is likely due to defective 
lysosomal degradation capacity rather than a blockage 
of autophagosome-lysosome fusion. Collectively, our 
data indicates that miR-29a inhibits PDAC autophagy 
by downregulation of TFEB and ATG9A.
Pancreatic cancer acquires chemo-resistance by 
inducing autophagy [15–17]. We found that miR-29a 
sensitized chemoresistant pancreatic cancer cells to 
gemcitabine treatment, decreased cancer cell viability, 
and enhanced gemcitabine-mediated cytotoxicity. 
Accordingly, upon gemcitabine treatment, miR-29a 
overexpression resulted in an increased LDH release 
[44, 45], caspase 3/7 activity, and cleaved caspase 3. CQ 
and BafA1 are known late stage autophagy inhibitors 
[54, 57]. The effect of miR-29a on LC3B and p62 
accumulation is similar to CQ and BafA1, suggesting 
that miR-29a serves as an effective late stage inhibitor 
of autophagy. miR-29 has been previously reported 
to induce cellular cytotoxicity/apoptosis by targeting 
anti-apoptotic protein Mcl-1 in cholangiocarcinoma 
[78]. However, the effect of miR-29 on Mcl-1 and 
gemcitabine-mediated cytotoxicity is not known in 
pancreatic cancer cells. Further studies are required to 
dissect the role of Mcl-1 in this mechanistic axis.
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Our functional studies demonstrate that 
overexpression of miR-29a inhibits pancreatic cancer 
cell migration and invasion through reversion of 
cancer cell EMT. Prior to metastasis, tumor cells 
undergo EMT, a process in which cells lose epithelial 
characteristics and gain a mesenchymal phenotype. 
Recent reports have implicated EMT is a characteristic 
feature of malignant transformation that contributes 
to the invasive/metastatic properties of a wide variety 
of cancers [79]. Overexpression of miR-29a resulted 
Figure 6: miR-29a inhibits invasive potential of PDAC cells. Panc-1 cells were transfected with control (CTRL) or miR-29a and 
plated into A. migration, and B. invasion assays. Migration and invasion data presented as average number of cells per 5 fields (n=3) ± 
S.E.M. and representative images shown below each graph. C. 10ug of total cell lysates from Panc-1 transfected with CTRL or miR-29a 
mimics were subjected to western blot analysis for epithelial marker, E-cadherin, and mesenchymal marker, Vimentin, and GAPDH was 
used as loading control. Relative quantification of band intensities normalized to GAPDH are shown below respective blots. D. Panc-1 cells 
were transfected with CTRL or miR-29a mimics and plated into soft agar assays. Data presented as average number of colonies per well 
(n=6) ± S.E.M. and representative images are shown below each graph. All experiments were repeated 3-4 times and representative data is 
presented. *p<0.05, **p<0.01.
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in an increase in epithelial marker, E-cadherin, and 
reduction in mesenchymal marker, Vimentin, indicating 
that reintroduction of miR-29a induces mesenchymal–
epithelial transition (MET) in pancreatic cancer cells. 
However, Vimentin is not a predicted miR-29 target 
(Targetscan), suggesting that miR-29a may induce MET 
transition through indirect effects rather than direct 
regulation of Vimentin. Of interest, autophagy has been 
shown to be concomitant with increased metastasis and 
EMT [11, 12]. Our findings demonstrate similar effects 
in which miR-29a mediated an inhibition of autophagy 
in tandem with MET transition and reduction of cancer 
cell invasive potential. It is possible that miR-29a reduces 
EMT in pancreatic cancer cells by inhibition of autophagy. 
However, further studies are warranted to dissect the 
precise underlying mechanisms.
To further study the function of miR-29a, we 
investigated the effect of miR-29a on anchorage 
independent growth of pancreatic cancer cells. Epithelial 
cells require attachment to a substrate in order to maintain 
structural polarity, function, and survival [80]. When 
this adhesion is lost, cells undergo anoikis, a form of 
programmed cell death induced by detachment [80, 
81]. Various cancers have been shown to avoid anoikis, 
leading to properties associated with metastasis and 
tumorigenesis [82]. We found that overexpression of miR-
29a significantly reduces the ability of pancreatic cancer 
cells to grow in an anchorage independent manner.
With the exception of AsPC-1, we observed 
consistent downregulation of all three miR-29 family 
members in various pancreatic cancer cell lines. AsPC-1 
contains homologous deletions in SMAD4, whereas the 
other cancer cell lines contain wildtype SMAD4 [83]. 
SMAD4 is a major downstream effector molecule of 
TGF-β1 signaling, forms a heterogeneous complex with 
pSMAD2/3, and regulates the target gene expression 
[84]. We and others have previously demonstrated that 
TGF-β1 downregulates miR-29 expression in other cell 
types through SMAD2/3/4 complex [39, 85]. Perhaps 
homologous deletion of SMAD4 in AsPC-1 derepresses 
miR-29 expression. However, this mechanism needs 
to be validated in PDAC. Furthermore, the regulatory 
mechanism associated with downregulation of miR-29 
has not been fully elucidated. The three miR-29 family 
members (miR-29a, -29b, -29c) are encoded from two 
co-transcribed miRNA clusters, miR-29a/b1 and 29c/b2 
located on Chromosome 7 and 1 respectively. Both miR-
29 loci have promoter regions containing c-Myc [86] 
Figure 7: Schematic diagram representing the role of miR-29a in PDAC autophagy and metastasis. miR-29a overexpression 
in pancreatic cancer cells decreases invasive potential and inhibits autophagy flux through downregulation of TFEB and ATG9A, resulting 
in increased sensitivity to GEM treatment. miR-29a may serve as a potential novel anti-autophagic/invasive agent to target PDAC.
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and SMAD3/4 [85] binding sites. It would be of interest 
to determine if c-Myc or SMAD4 regulates miR-29 
expression in pancreatic cancer cells, as both of them have 
been indicated to play a critical role in PDAC [87, 88].
The downregulation and anti-tumorigenic effects 
of miR-29 have been reported in a wide variety of 
cancers [70–72]. Furthermore, autophagy has been 
implicated in a number of carcinomas to promote 
metastasis [9] and induce chemoresistance [89–91]. It 
would be of immense interest to evaluate the role of 
miR-29 in autophagy of other cancers, as this would 
shed light on whether the mechanism of autophagy 
inhibition we have found is ubiquitous in cancer 
pathogenesis or idiosyncratic to pancreatic cancer. 
Furthermore, our findings need to be validated in vivo 
to translate our findings into the clinic. Nevertheless, 
our studies reveal a novel role of miR-29a in PDAC 
autophagy and provide evidence for its use as an 
autophagy inhibitor and novel therapeutic agent in 
combination with gemcitabine to target PDAC.
MATERIALS AND METHODS
Cell lines
Normal human pancreatic epithelial cell lines HPNE 
(ATCC, CRL-4023) and HPDE (AddexBio, T0018001) 
were grown in Dulbecco’s Modified Eagle Medium 
(DMEM) (Life Technologies, 11965-092) supplemented 
with 10% fetal bovine serum (FBS). Panc-1 (ATCC, 
CRL-1469) and MIA PaCa-2 (ATCC, CRL-1420) were 
grown in DMEM supplemented with 10% FBS, 100units 
ml-1 penicillin, and 100mg ml-1 streptomycin. COLO 357 
[92], AsPC-1 (ATCC, CRL-1682), and BxPC-3 (ATCC, 
CRL-1687) were grown in Roswell Park Memorial 
Institute (RPMI) 6140 (Life Technologies, 11875-093) 
supplemented with 10% FBS, 100units ml-1 penicillin, and 
100mg ml-1 streptomycin.
RNA purification
Total RNA was extracted from cells using Trizol 
extraction kit (Life Technologies, 15596018) according 
to the manufacturer’s protocol. The quantity and purity 
of RNA was determined by OD260/280 reading using a 
Nanodrop spectrophotometer.
Measurements of RNA by qPCR
Mature miR-29 family member expression and 
p62 mRNA expression levels were measured by TaqMan 
Assays (Applied Biosystems): miR-29a (ID:002112); 
miR-29b (ID:000413); and miR-29c (ID:000587) ; and 
SQSTM1/p62 (ID: 4331182). U6 snRNA (ID:001973) or 
ACTB (ID: 4331182) were used as a endogenous controls 
to normalize miR-29 expression and p62 expression 
respectively. Samples were analyzed using ABI 7500 
Real-Time PCR machine. Samples were run in triplicates 
with 0.2 thresholds, and the ΔΔCT method was used for 
relative miR-29 expression analysis.
Western blot analyses of proteins
Total cell protein was isolated using RIPA buffer 
(Thermo Scientific, PI-89900) and quantified using 
BCA Protein Assay Kit (Pierce Biotechnology, 23225). 
Protein samples were run through SDS-PAGE and were 
transferred to polyvinylidene fluoride membrane, followed 
by a block in 10% dried non-fat milk, and then probed with 
primary antibodies against Caspase-3 (Novus Biological, 
9662S ), Procaspase-3 (Cell Signaling, 9662S), LC3B 
(Novus Biological, NB100-2220), SQSTM1/p62 (Thermo 
Scientific, H00008878-M01), LAMP-2 (Santa Cruz, sc-
18822), ATG9A (ab108338), TFEB (Cell Signaling, 
4240), GAPDH (Millipore, MAB374) and corresponding 
HRP conjugated goat anti-rabbit (Santa Cruz, sc-2004), 
goat anti-mouse (Bio-Rad, 172-1011), or donkey anti-
goat (Santa Cruz, sc-2020) secondary antibodies. Proteins 
were visualized and quantified using chemiluminescent 
detection kit (GE Healthcare, Amersham ECL) and 
exposed to X-ray film (Thermo Scientific, CL-X Posure 
Film) or captured on an Amersham Imager 600 (GE 
Healthcare, CCD Model). The intensity for each band 
was densitometrically quantified and normalized against 
loading control using ImageJ software.
Transfection of cultured cells
Exponentially growing cancer cells were seeded 
in 6 well plates at 1×105 cells per well or 12 well plates 
at 5×104 per well and allowed to adhere overnight and 
transfected with indicated concentrations (10μM, 20μM) 
of control (GE Dharmacon, CN-001000-01) or miR-29a 
(GE Dharmacon, C-300504-07) mimics, or 1μM siRNA 
using siCTRL (GE Dharmacon, D-001810-10-05), siTFEB 
(GE Dharmacon, L-009798-00-0005), and siATG9A (GE 
Dharmacon, L-014294-01-0005) using DharmaFECT®1 
(GE Dharmacon, T-2001-01) as per the manufacturer’s 
protocol. Total protein or RNA was isolated at 24 hours 
post-transfection for western blot or qPCR analysis 
respectively as described above.
Migration and invasion measurements
1×104 cells (Panc-1 or MIA PaCa-2) transfected with 
20nM control or miR-29a mimics using DharmaFECT®1 
were plated in triplicate in the upper chambers of 8μm 
transwells (Falcon, 353097) in 100μl serum-free media 
and 750μl 10% serum containing media in the lower 
chamber of 24-well plates and incubated at 37°C for 24 
hours. For invasion assays, 80μl of 1:5 diluted matrigel 
(BD, 354234) was pre-coated in the upper chambers and 
allowed to solidify prior to plating cells. 24 hours post-
seeding, membranes were washed twice with PBS, fixed 
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with 4% paraformaldehyde, and stained with 0.1% crystal 
violet in 20% ethanol. Any cells remaining in the upper 
chamber were carefully removed, and cells migrated/
invaded on to the lower membrane were imaged and 
counted. For each well, 5 random fields were counted, and 
average number of cells per field was presented.
Measurements of cell viability, cytotoxicity, and 
caspase activity
5×103 pancreatic cancer cells per well (Panc-1, MIA 
PaCa-2, or COLO 357) were plated in 96 well plates and 
grown at 37°C for 24 hours. Cells were then transfected 
with 20nM mimic control or miR-29a mimic using 
DharmaFECT®1 for 24 hours. Transfection media was 
then removed and replaced with complete media, and cells 
were allowed to recover for 24 hours and subsequently 
treated with varying concentrations of gemcitabine (0μM, 
0.1μM, 1μM, 10μM, 100μM). Cell viability was measured 
at 72 hours post-gemcitabine treatment by adding 10ul 
Cell Counting Kit-8 (CCK8) reagent (Dojindo, CK04) and 
absorbance was measured at 450nm. For cell viability with 
Chloroquine (CQ) and BafilomycinA1 (BafA1) treatment, 
cells were treated with 25μM CQ (Sigma Aldrich, C6628) 
or 10μM BafA1 (Sigma Aldrich, B1793) in combination 
with 10μM gemcitabine for 48 hours, and viability 
was measured using CCK8 kit as described above. For 
cytotoxic effects and caspase activity, pancreatic cancer 
cells (Panc-1, MIA PaCa-2) were transfected with mimic 
control or miR-29a mimic as described above and treated 
with 10μM gemcitabine for 24-48 hours. For cytotoxic 
effects, lactate dehydrogenase release was determined 
using Promega CytoTox-ONE Homogeneous Membrane 
Integrity Assay (Promega, G7890) and fluorescence was 
measured at 560/590nm. Caspase activity was determined 
using Promega Apo-ONE Homogenous Caspase-3/7 
Assay Kit (Promega, PRG7790) with fluorescence 
measured at 490/530nm.
Soft agar assays
3×105 pancreatic cancer cells per well (Panc-1 or 
MIA PaCa-2) were plated in 6 well plates and grown at 
37°C for 24 hours. Cells were then transfected with 20nM 
mimic control or miR-29a mimic using DharmaFECT®. 
1.5×103 pancreatic cancer cells (Panc-1 or MIA PaCa-2) 
transfected with control or miR-29a mimics were plated per 
well in a 6 well plate containing 0.5% top agarose and 1% 
bottom agarose (BioRad, 162-0137). After 20 days, colonies 
were stained with crystal violet and were counted under low 
power bright field microscopy for positive colonies.
Luciferase reporter assay
The 3’UTR containing predicted miR-29 binding 
sites, both wild type and mutant, for ATG9A and TFEB 
were cloned into pmirGLO Dual-Luciferase miRNA 
Target Expression Vector (Promega, #E1330) downstream 
of the firefly luciferase open reading frame. 5×103 
pancreatic cancer cells per well (Panc-1 or MIA PaCa-2) 
were plated in 96 well plates and grown at 37°C for 24 
hours. Cells were then co-transfected for 24hrs with 10nM 
mimic control or miR-29a mimic and 100ng of pmirGLO 
Dual-Luciferase miRNA Target Expression Vector 
containing each respective 3’UTR binding site using 
DharmaFECT Duo Transfection Reagent (GE, T-2010-
02). Cells were transfected for 24 hours, and luciferase 
levels were measured 24 hours post-transfection using 
Dual-Glo® Luciferase Assay System (Promega, #E2920). 
Firefly luciferase luminescence was normalized to renilla 
luciferase activity for each transfected well.
Autophagy assays
For assessment of miR-29 effects on autophagy flux 
via immunoblotting, 1×105 pancreatic cancer cells per 
well (Panc-1, MIA PaCa-2, or COLO 357) were plated in 
12 well plates and grown at 37°C for 24 hours. Cells were 
then transfected with 10nM control or miR-29a mimics 
using DharmaFECT®1. 24 hours post-transfection, cells 
were treated with 25μM CQ in complete media for 3-6 
hours. Subsequently, total proteins were harvested and 
subjected to western blot analysis as described above. 
Lentivirus encoding GFP-LC3B were generated using 
plasmid (GeneCopoeia, EX-T0824-Lv103) in HEK293 
cells (ATCC, CRL-1573) via standard HEPES/Calcium 
Phosphate transfection. Stable Panc-1 GFP-LC3B 
cells were generated by transducing exponentially 
growing Panc-1 cells in T-75 flask. GFP positive cells 
were selected by flow cytometry and were expanded 
for one week prior to conducting experiments. For 
immunofluorescence imaging, cells were fixed with 4% 
PFA and permeabilized using 0.1% triton and blocked 
using 1% BSA. Primary LAMP-2 antibody (Santa 
Cruz, SC18822) was incubated overnight, followed by 
1 hour secondary Alexa Fluor® 647 antibody (Abcam, 
ab150079) incubation and 10ug/mL Hoechst Nuclear 
Stain (Life Technologies, ab150083). Eight 0.5 micron 
Z-stack sections were captured using the Opera (Perkin 
Elmer) fluorescent microscope and final images were 
deconvolved and analyzed using Volocity imaging 
analysis software (Perkin Elmer). Quantifications for 
number of GFP-LC3B positive compartments and 
colocalization of GFP-LC3B and LAMP-2 were taken 
from 4 random fields with 8-10 cells per field.
Statistics
ANOVA with Tukey’s post-hoc test and 2-tailed 
Student’s t tests were used to test for statistical 
significance. P < 0.05 was considered statistically 
significant.
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